22 gennaio 2021 07:37
Fonte: Adnkronos
#salute-e-benessere
- BOULDER, Colo., Jan. 21, 2021 /PRNewswire/ AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the startup, strategic development and operational excellence in large-scale biologics production at its Boulder, Colorado site. Effective February 1, 2021, David Stewart will join the Boulder team as the General Manager/Site Head.
Mr. Stewart brings a servant leader mindset, with a proven record of delivering best-in-class supply for client organizations and the patients they serve. He promotes accountability, innovation, collaboration, and agility to build high-performance teams. He also brings more than 20 years of leadership experience in the biotechnology and manufacturing industry, including roles with Biogen and Genentech. In his new role, Mr. Stewart will support the continuous growth of the Site, while partnering cl
AGC Biologics Appoints David Stewart as the New General Manager/Site Head of the Boulder, Colorado Site
USA - English
Share this article
Share this article
BOULDER, Colo., Jan. 21, 2021 /PRNewswire/ AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the startup, strategic development and operational excellence in large-scale biologics production at its Boulder, Colorado site. Effective February 1, 2021, David Stewart will join the Boulder team as the General Manager/Site Head.
Mr. Stewart brings a servant leader mindset, with a proven record of delivering best-in-class supply for client organizations and the patients they serve. He promotes accountability, innovation, collaboration, and agility to build high-performance teams. He also brings more than 20 years of leadership experience in the biotechnology and manufacturing industry, including roles with Biogen and Genentech.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
Achilles TherapeuticsJanuary 8, 2021 GMT
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
London, UK 7 January 2021 – Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Arjan Roozen as VP, Site Head and General Manager, with responsibility for scaling up Achilles’ manufacturing operations to supply cell therapy products for late-stage clinical studies and commercial supply. Arjan brings over 25 years of experience in the field of advanced therapies and Good Manufacturing Practices (GMP) operations, from early phase to commercial manufacture.
Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
About Vertex Pharmaceuticals
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.